Sort   by:  
 Page size 
ProteomicsALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
Anaplastic lymphoma kinase (ALK) fusion variants in non-small-cell-lung cancer (NSCLC) consist of numerous dimerising fusion partners, with the most common being EML4. Clinical data suggests that the degree of treatment benefit in response to ALK tyrosine kinase inhibitors (TKIs) differs among the v...
ORGANISM(S): Homo sapiens (Human) 
2023-02-16 | PXD035100 | Pride
Human Nsclcl Orbitrap fusion lumos 
TranscriptomicsTranscriptomic profiling of three different neuroblastoma cell lines (CLB-BAR, CLB-GE and SK-N-AS) in response to ALK inhibition
Anaplastic Lymphoma Kinase (ALK) is a tyrosine kinase receptor which is a clinical target of major interest in cancer, including neuroblastoma. To better understand ALK signaling, three different neuroblastoma cell lines (CLB-BAR, CLB-GE and SK-N-AS) were cultured for 1hr and 24hrs in control condit...
ORGANISM(S): Homo sapiens 
2018-09-01 | E-MTAB-6654 | biostudies-arrayexpress
ProteomicsPhosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cells lines reveals conserved oncogenic pathways
Neuroblastoma is a neural crest-derived embryonal tumor or the postganglionic sympathetic nervous system. Neuroblastomas show heterogeneous biologic and clinical features and , whereas a subset may undergo spontaneous differentiation or regression with little or no therapy, the majorities are diffic...
ORGANISM(S): Homo sapiens (Human) 
2018-11-27 | PXD011187 | Pride
Alk inhibition Oncogenic Neuroblastoma Phosphoproteome Pathways 
TranscriptomicsRNA-seq of human neuroblastoma cell lines where RET is knocked out
ALK is driving neuroblastoma (NB) and RET has been shown to be a downstream target of ALK signaling in NB. To get a better understanding of the role of RET in NB, the gene was knocked out in SKNAS cell lines.
ORGANISM(S): Homo sapiens 
2021-04-14 | E-MTAB-10032 | biostudies-arrayexpress
Sort   by:  
 Page size